Clinical Trial Update: Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial update evaluating disitamab vedotin, fruquintinib, and tislelizumab as second-line therapy for HER2-positive gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Fruquintinib (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: HER2-positive Gastric Cancer, Immunotherapy | Phase 1, Phase 2 | Status: UNKNOWN